Pharmaseal offers no-cost CTMS for COVID-19 trials
Pharmaseal International is enabling academic institutions and pharmaceutical organizations to use Engility clinical trial management system (CTMS) for clinical research centered around COVID-19. According to the company, the cloud-based CTMS can be implemented rapidly for management of a clinical trial’s full cycle, including regulatory documentation.
Facilitating collaboration
Daljit Cheema, Pharmaseal CEO, told Outsourcing-Pharma that the CTMS has been engineered to enable collaboration, empowering users to work in the same system or integrate with other eClinical systems.
“Our platform is designed to improve upon internal and external communication and enhance overall supply-chain management,” he said. “It is designed to manage trials of all complexity, and therefore can substantially reduce the cost and time spent on duplicative or even unnecessary tasks that exist when not using a modern trial management solution.”
What’s more, Cheema said, the company felt the need for such tools in the face of the global pandemic.
“We believe that our intuitive and user-friendly system, which is rapidly implemented, can provide companies that are running COVID-19 trials a more secure, regulated system to plan, track and manage their trials increasing their efficiency and effectiveness to manage these clinical trials,” he said. “It is our belief that our system can take some pressure off companies, allowing them to focus on bringing novel medicines to market.”
Improving efficiency
Cheema added that facilitating collaboration makes a clinical trial organization more efficient, cost-effective and insightful.
“This focus on interaction across multiple stakeholder groups not only provides greater insight into clinical trial data, but also reduces inefficiencies that have previously existed with siloed business functions,” he said. “It is not just the system itself, but the standards that you build by using the system that will aid in streamlining processes and ultimately reducing cost pressures.”
Cheema also explained the Engility CTMS enables users to readily centralize trial information, with a high degree of control and unified governance among collaborators. Additionally, it facilitates remote working, monitoring and sharing of information.
Engility is a software-as-a-service (SaaS) cloud platform engineered to deliver new product updates in a timely manner, within a continuous validation framework designed to accelerate innovation. According to the company, the platform is made to be flexible and scalable to meet an organization’s specific needs.
